BridgeMD
New treatment option for Sensory Neuronopathy
Official title Clinical Evaluation of Sensory Neuronopathies: the Neuronoscore Study
ClinicalTrials.gov ID: NCT07651540
What this study is testing
- What it's testing
- Sensory neuronopathies (SN) are a group of rare neuropathies characterized by selective destruction of sensory neurons located in the dorsal root ganglia. SN may result from a wide range of etiologies, particularly paraneoplastic, autoimmune, toxic, and genetic causes.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patient affiliated with or beneficiary of a social security system
- Patient having received appropriate study information
- Adult patient ≥18 years old, male or female
- Patient diagnosed with probable SN according to Camdessanché et al. diagnostic criteria
- SN with one of the following etiologies: Paraneoplastic SN with anti-Hu or anti-CV2/CRMP5 antibodies SN associated with Sjögren's syndrome, systemic...
You likely can't join if
- Patient unable to understand or read French
- Patient refusal to participate
- Patient known to have another neuropathy phenotype and/or etiology that could significantly influence clinical scales and electrophysiological...
- Diabetes mellitus
- Significant alcohol consumption
- Severe chronic kidney disease (GFR \<30 ml/min)
See the full eligibility criteria
- Patient affiliated with or beneficiary of a social security system
- Patient having received appropriate study information
- Adult patient ≥18 years old, male or female
- Patient diagnosed with probable SN according to Camdessanché et al. diagnostic criteria
- SN with one of the following etiologies: Paraneoplastic SN with anti-Hu or anti-CV2/CRMP5 antibodies SN associated with Sjögren's syndrome, systemic lupus erythematosus, or primary biliary cholangitis...
- Patient unable to understand or read French
- Patient refusal to participate
- Patient known to have another neuropathy phenotype and/or etiology that could significantly influence clinical scales and electrophysiological parameters, including:
- Diabetes mellitus
- Significant alcohol consumption
- Severe chronic kidney disease (GFR \<30 ml/min)
- Vitamin B12 and/or vitamin E deficiency
- Vitamin B6 excess
- Chemotherapy other than platinum salts
- HIV infection
The study team makes the final eligibility decision.
Where it's taking place
- Angers, France
- Clermont-Ferrand, France
- Grenoble, France
- Lille, France
- Limoges, France
- Lyon, France
- Marseille, France
- Nancy, France
- Nantes, France
- Nice, France
- Paris, France
- Saint-Etienne, France
- Saint-Pierre, France
- Strasbourg, France
- Toulouse, France
- Geneva, Switzerland
- Lausanne, Switzerland
- Sion, Switzerland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Angers, France; Clermont-Ferrand, France; Grenoble, France; Lille, France; Limoges, France; Lyon, France and 12 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.